Lenacapavir submitted to the US FDA with an indication for HIV PrEP
20 December 2024. Related: Early access, Antiretrovirals, Treatment access, HIV prevention and transmission.
Treatment access
Management of drug resistance to integrase inhibitors: results from an international perinatal virtual clinic
1 November 2024. Related: Treatment access, Paediatric care, Drug resistance.
Helsinki Declaration: 2024 edition upholds ethical access to treatment
23 October 2024. Related: Treatment access, HIV prevention and transmission.
Urgency of planning broad vaccine-like access to lenacapavir PrEP globally
13 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
HIVR4P 2024: Context of PrEP in Latin America
7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
HIVR4P 2024: Introduction
7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
Gilead announces plans to support generic lenacapavir for low-income countries
2 October 2024. Related: Treatment access.
NICE defers decision on CAB-LA as PrEP needing more information
27 September 2024. Related: Treatment access, HIV prevention and transmission.
UNAIDS reports debt crisis obstructs HIV response
19 September 2024. Related: Treatment access, Other news.
AIDS 2024: Including people living with HIV in non-HIV research
11 September 2024. Related: Conference reports, Treatment access, Cancer and HIV, Treatment advocacy.
Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
26 July 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
CHAI six-monthly market report (July 2024)
16 July 2024. Related: Treatment access, On the web.
Uganda Court rejects appeal against the LGBTQ+ hate law
5 April 2024. Related: Special reports, Treatment access.
CROI 2024: Opening lecture calls for scientists to speak up for LGBTQ+ rights in Uganda
24 March 2024. Related: Conference reports, Treatment access, Women's health, Pregnancy, Vaccines and microbicides.
CROI 2024: Promising results from first study of long-acting treatment in Africa
10 March 2024. Related: Conference reports, Antiretrovirals, Treatment access.
Uganda hate law blocks HIV research: join 300 leading researchers in sign-on protest
4 January 2024. Related: Special reports, Treatment access, Treatment advocacy, Research studies.
First-line ART drops below US $45 a year for low-income countries
1 December 2023. Related: Antiretrovirals, Treatment access.
CHAI 2023 market report: decline in HIV funding threatens 20 years of progress
1 December 2023. Related: Treatment access.
Implications of restrictions on reproductive rights for HIV care in the USA and beyond
6 April 2023. Related: Conference reports, Treatment access, Women's health, Pregnancy.
CHAI 2022 report on global access to ART
1 December 2022. Related: Treatment access.
ViiV licenses long-acting cabotegravir (CAB-LA) for generic access
1 June 2022. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.
Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits
2 May 2022. Related: Antiretrovirals, Treatment access.
NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales
30 November 2021. Related: Antiretrovirals, Treatment access.
Darunavir/ritonavir price now US $210 for global access
17 September 2021. Related: Treatment access.
UK government to cut international HIV support to UNAIDS by 80%
3 May 2021. Related: Treatment access.
New formulation of dolutegravir will make modern ART available for babies and young children at less than $120 a year
9 December 2020. Related: Antiretrovirals, Treatment access, Paediatric care.
Dolutegravir/lamivudine FDC recommended by NHS England
12 March 2020. Related: Treatment access.
US government claims patent infringement by Gilead Sciences over use of F/TAF and FTC/TDF as PrEP
15 November 2019. Related: Treatment access, HIV prevention and transmission.
UK contributes £1.4 billion towards Global Fund for 2020 to 2022
18 October 2019. Related: Treatment access.
Global Fund raises US$14 billion for 2020 to 2022
18 October 2019. Related: Treatment access.
Scotland approves dual therapy with dolutegravir/lamivudine (Dovato)
30 September 2019. Related: Antiretrovirals, Treatment access.
UK HIV organisations call for urgent review of crisis in sexual health funding
30 September 2019. Related: Treatment access, Other news.
Two pints of lager and a packet of PrEP please: London price for HIV PrEP drops to £17.50
19 June 2019. Related: Treatment access, HIV prevention and transmission.
Activists challenge block to generic PrEP and current US price of TDF/FTC
19 June 2019. Related: Treatment access, HIV prevention and transmission.
BHIVA preconference: U=U and HIV and immigration detention
30 April 2019. Related: Conference reports, Treatment access, HIV prevention and transmission.
Civil society organisations push for a target of $18 billion for the Global Fund’s sixth replenishment
20 February 2019. Related: Treatment access.
BMJ survey reports lack of NHS planning for Brexit: impact on drug supplies unknown
21 January 2019. Related: Treatment access.
BASHH, BHIVA, HIVPA and NHIVNA statement on a no-deal Brexit
21 January 2019. Related: Treatment access.
UK-CAB statement on Brexit, HIV and access to medicines
21 January 2019. Related: Treatment access.
Model predicts benefit of dolutegravir for all in sub-Saharan Africa outweighs risk
21 January 2019. Related: Treatment access.
Activists demand $1 a day access to bedaquiline for MDR TB
13 November 2018. Related: Treatment access, TB coinfection.
UK government funding cuts leave sexual health and HIV care at breaking point
19 October 2018. Related: Treatment access.
Brazilian court suspends patent on hepatitis C medicine sofosbuvir
19 October 2018. Related: Treatment access, Hepatitis coinfection.
Namibia close to achieving 90-90-90 targets
24 August 2018. Related: Conference reports, Treatment access.
Viral load testing in Latin America and the Caribbean
24 August 2018. Related: Conference reports, Treatment access, Diagnostics.
Access to viral load testing increased from 14% to 61% over two years in Côte d’Ivoire
24 August 2018. Related: Conference reports, Treatment access, Guidelines.
Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil
3 August 2018. Related: Conference reports, Antiretrovirals, Treatment access.
Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries
21 May 2018. Related: Treatment access.
Generic manufacturers from South Africa and South Korea join Medicine Patent Pool (MPP)
21 May 2018. Related: Treatment access.
WHO releases first list for essential diagnostics
21 May 2018. Related: Treatment access.
Campaign forces Government U-turn on linking NHS data to immigration service
21 May 2018. Related: Treatment access, Other news.
Almost 1 in 8 people with symptoms turned away from sexual health clinics in SE London: 40% are under 25 and 6% under 18 years old
1 May 2018. Related: Conference reports, Treatment access, Women's health, Pregnancy, HIV prevention and transmission.
Drug cost savings from routine use of generic ARVs: safety and efficacy in practice
1 May 2018. Related: Conference reports, Antiretrovirals, Treatment access.
Continued demands to stop NHS Digital linking medical records to deportation services
1 May 2018. Related: Treatment access, Other news.
FDA grants tentative approval to first DTG/FTC/TAF FDC
23 February 2018. Related: Antiretrovirals, Treatment access.
Universal ART on diagnosis: approved by NHS England
23 February 2018. Related: Treatment access.
75% of WHO essential medicines could be cheaper: UK and South Africa both overpay
9 February 2018. Related: Treatment access.
London clinic to prescribe generic PrEP privately at £55 for 30 tablets
9 February 2018. Related: Treatment access, HIV prevention and transmission.
MSF secures generic hepatitis C treatment at $120 per course
28 November 2017. Related: Treatment access, Hepatitis coinfection, Other news.
Generic dolutegravir-based FDCs at US $75 a year for low- and middle-income countries
1 October 2017. Related: Treatment access.
UK donates well to the Global Fund, but slashed bilateral aid for HIV
1 October 2017. Related: Treatment access.
Dozens of countries left out of new PEPFAR strategy, threatening the global AIDS response
1 October 2017. Related: Treatment access.
NHS access to PrEP in the UK: country update
1 October 2017. Related: Treatment access, HIV prevention and transmission.
Generic PrEP in France and Scotland challenges access across the UK
1 October 2017. Related: Treatment access, HIV prevention and transmission.
Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study
10 August 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Treatment access.